Crayol Pharmaceutical Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.60 M
- Company Age 6 Year, 11 Months
- Last Filing with ROC 31 Mar 2020
- Revenue Growth 3.55%
- Profit Growth -885.92%
- Ebitda -74.21%
- Net Worth -12.44%
- Total Assets -12.38%
About Crayol Pharmaceutical
Crayol Pharmaceutical Private Limited (CPPL) is a Private Limited Indian Non-Government Company incorporated in India on 23 February 2018 (Six years and 11 months 17 days old ). Its registered office is in Surat, Gujarat, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2020. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.60 M, as per Ministry of Corporate Affairs (MCA) records.
Shashibhan Shukla, Rubi Singh, and Prabhat Khanna serve as directors at the Company.
Company Details
-
Location
Surat, Gujarat, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U74999GJ2018PTC100957
-
Company No.
100957
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
23 Feb 2018
-
Date of AGM
31 Dec 2020
-
Date of Balance Sheet
31 Mar 2020
-
Listing Status
Unlisted
-
ROC Code
Roc Ahmedabad
Industry
Who are the key members and board of directors at Crayol Pharmaceutical?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Prabhat Khanna
|
Director | 07-Nov-2019 | Current |
|
Shashibhan Shukla
|
Director | 23-Feb-2018 | Current |
|
Rubi Singh
|
Director | 02-Sep-2019 | Current |
Financial Performance of Crayol Pharmaceutical.
Crayol Pharmaceutical Private Limited, for the financial year ended 2020, experienced modest growth in revenue, with a 3.55% increase. The company also saw a substantial fall in profitability, with a 885.92% decrease in profit. The company's net worth observed a substantial decline by a decrease of 12.44%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Crayol Pharmaceutical?
Unlock access to Crayol Pharmaceutical's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
-
Creyal Pharma Private LimitedShashibhan Shukla is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Crayol Pharmaceutical?
Unlock and access historical data on people associated with Crayol Pharmaceutical, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Crayol Pharmaceutical, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Crayol Pharmaceutical's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
